World's Best Scientists 2026 revealed!
Carlo Gambacorti-Passerini

Carlo Gambacorti-Passerini

D-Index & Metrics

Medicine

D-Index
87
Citations
41834
World Ranking
13413
National Ranking
513

Overview

Carlo Gambacorti-Passerini is affiliated with the University of Milano-Bicocca in Italy, focusing primarily on the field of medicine with a specialization in hematology.

The scientist's research contributions span several interconnected subfields, including hematology, genetics, public health, oncology, and molecular biology. This interdisciplinary approach is reflected in the topics they have extensively investigated:

  • Chronic Myeloid Leukemia Treatments
  • Chronic Lymphocytic Leukemia Research
  • Acute Lymphoblastic Leukemia Research
  • Lymphoma Diagnosis and Treatment
  • Eosinophilic Disorders and Syndromes
  • Acute Myeloid Leukemia Research
  • Myeloproliferative Neoplasms: Diagnosis and Treatment

Their recent publications include a range of studies published between 2020 and 2022, appearing in peer-reviewed journals with significant scientific reputations. Selected papers are as follows:

  • "Clinical characteristics and risk factors associated with COVID-19 severity in patients with haematological malignancies in Italy: a retrospective, multicentre, cohort study" (2020), The Lancet Haematology
  • "Integrative pathway enrichment analysis of multivariate omics data" (2020), Nature Communications
  • "Cancer LncRNA Census reveals evidence for deep functional conservation of long noncoding RNAs in tumorigenesis" (2020), Communications Biology
  • "Bosutinib versus imatinib for newly diagnosed chronic phase chronic myeloid leukemia: final results from the BFORE trial" (2022), Leukemia
  • "Phase 3 trial of gilteritinib plus azacitidine vs azacitidine for newly diagnosed FLT3mut+ AML ineligible for intensive chemotherapy" (2022), Blood

Frequent co-authors of this researcher, indicating active collaboration within the scientific community, include:

  • Rocco Piazza
  • Luca Mologni
  • Andrea Aroldi
  • Tim H. Brümmendorf
  • Pau Montesinos

The scientist has published regularly in specific venues, highlighting established channels for their research dissemination. The most common publication venues are:

  • Blood
  • HemaSphere
  • Clinical Lymphoma Myeloma & Leukemia
  • Journal of Clinical Oncology
  • Nature Communications

Best Publications

  • Pan-cancer analysis of whole genomes

    Peter J. Campbell;Gad Getz;Jan O. Korbel;Joshua M. Stuart

  • Hematologic and cytogenetic responses to imatinib mesylate in chronic myelogenous leukemia

    Hagop M Kantarjian;Charles Sawyers;Andreas Hochhaus;Francois Guilhot

  • Clinical and biological implications of driver mutations in myelodysplastic syndromes.

    Elli Papaemmanuil;Moritz Gerstung;Luca Malcovati;Sudhir Tauro

  • Imatinib induces hematologic and cytogenetic responses in patients with chronic myelogenous leukemia in myeloid blast crisis: results of a phase II study

    Charles L. Sawyers;Andreas Hochhaus;Eric Feldman;John M. Goldman

  • Imatinib induces durable hematologic and cytogenetic responses in patients with accelerated phase chronic myeloid leukemia: results of a phase 2 study.

    Moshe Talpaz;Richard T. Silver;Brian J. Druker;John M. Goldman

  • Somatic SF3B1 Mutation in Myelodysplasia with Ring Sideroblasts

    E. Papaemmanuil;M. Cazzola;J. Boultwood;L. Malcovati

  • A Phase 2 Trial of Ponatinib in Philadelphia Chromosome–Positive Leukemias

    Jorge E. Cortes;D. W. Kim;J. Pinilla-Ibarz;P. Le Coutre

  • Patterns of somatic structural variation in human cancer genomes

    Yilong Li;Nicola D Roberts;Jeremiah A Wala;Jeremiah A Wala;Ofer Shapira;Ofer Shapira

  • The price of drugs for chronic myeloid leukemia (CML) is a reflection of the unsustainable prices of cancer drugs: from the perspective of a large group of CML experts

    Camille Abboud;Ellin Berman;Adam Cohen

  • Induction of resistance to the Abelson inhibitor STI571 in human leukemic cells through gene amplification.

    Philipp le Coutre;Elena Tassi;Marileila Varella-Garcia;Rossella Barni

  • Selective cytotoxicity of betulinic acid on tumor cell lines, but not on normal cells

    Valentina Zuco;Rosanna Supino;Sabina C Righetti;Loredana Cleris

  • Bosutinib Versus Imatinib in Newly Diagnosed Chronic-Phase Chronic Myeloid Leukemia: Results From the BELA Trial

    Jorge E. Cortes;Dong Wook Kim;Hagop M. Kantarjian;Tim H. Brümmendorf;Tim H. Brümmendorf

  • Activity of Bosutinib, Dasatinib, and Nilotinib Against 18 Imatinib-Resistant BCR/ABL Mutants

    Sara Redaelli;Rocco Piazza;Roberta Rostagno;Vera Magistroni

  • Molecular mechanisms of resistance to imatinib in Philadelphia-chromosome-positive leukaemias

    Carlo B Gambacorti-Passerini;Rosalind H Gunby;Rocco Piazza;Annamaria Galietta

  • Safety and efficacy of bosutinib (SKI-606) in chronic phase Philadelphia chromosome–positive chronic myeloid leukemia patients with resistance or intolerance to imatinib

    Jorge E. Cortes;Hagop M. Kantarjian;Tim H. Brümmendorf;Dong Wook Kim

  • Multicenter Independent Assessment of Outcomes in Chronic Myeloid Leukemia Patients Treated With Imatinib

    Carlo Gambacorti-Passerini;Laura Antolini;Franois Xavier Mahon;Francois Guilhot

  • Ponatinib efficacy and safety in Philadelphia chromosome–positive leukemia: final 5-year results of the phase 2 PACE trial

    Jorge E. Cortes;Dong Wook Kim;Javier Pinilla-Ibarz;Philipp D. le Coutre

  • In Vivo Eradication of Human BCR/ABL-Positive Leukemia Cells With an ABL Kinase Inhibitor

    Philipp le Coutre;Luca Mologni;Loredana Cleris;Edoardo Marchesi

  • Role of α1 Acid Glycoprotein in the In Vivo Resistance of Human BCR-ABL+ Leukemic Cells to the Abl Inhibitor STI571

    Carlo Gambacorti-Passerini;Rossella Barni;Philipp le Coutre;Massimo Zucchetti

  • Bosutinib Versus Imatinib for Newly Diagnosed Chronic Myeloid Leukemia: Results From the Randomized BFORE Trial

    Jorge E. Cortes;Carlo Gambacorti-Passerini;M. W. Deininger;Michael J. Mauro

Frequent Co-Authors

Jorge E. Cortes
Jorge E. Cortes Augusta University
Hagop M. Kantarjian
Hagop M. Kantarjian The University of Texas MD Anderson Cancer Center
Tim H. Brümmendorf
Tim H. Brümmendorf RWTH Aachen University
Michael W. Deininger
Michael W. Deininger University of Utah
Andreas Hochhaus
Andreas Hochhaus Friedrich Schiller University Jena
Michele Baccarani
Michele Baccarani University of Bologna
Jane F. Apperley
Jane F. Apperley Imperial College London
Francois Guilhot
Francois Guilhot Grenoble Alpes University
Moshe Talpaz
Moshe Talpaz University of Michigan–Ann Arbor
Leonardo Scapozza
Leonardo Scapozza University of Geneva

If you think any of the details on this page are incorrect, let us know.

Report an issue

We appreciate your kind effort to assist us to improve this page, it would be helpful providing us with as much detail as possible in the text box below:

Related Online Degrees & Career Pathways

In addition to traditional medical degrees, students are increasingly exploring alternative healthcare career pathways through flexible online programs. With the healthcare industry rapidly evolving, online degrees can open doors to a variety of high-demand fields without the need to attend campus full-time.

For those interested in pharmaceuticals, online pharmacy schools offer accredited programs leading to rewarding pharmacy careers. Similarly, managing medical data is a critical role, and many students pursue their education through online schools for health information management to work in record keeping, compliance, and data analysis.

The demand for skilled billing professionals is also on the rise. Affordably priced medical billing and coding online courses cost significantly less than traditional education, making this a popular choice for career changers and those seeking quick entry into the workforce.

Additionally, those looking to advance their nursing careers can find flexible options through the cheapest online fnp programs, positioning themselves for roles as family nurse practitioners (FNPs) in primary care settings.

Best Scientists Citing Carlo Gambacorti-Passerini

Trending Scientists

Recently Published Articles